Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 17/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.71 |
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | JAK1 | P23458 | 2/20 | 0.56 |
| ▸ | TYK2 | P29597 | 2/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.54 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.54 |
| ▸ | FER | P16591 | 1/20 | 0.53 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14842037 | 1.00 | SYK (0.77) | SYKKCNH2JAK2JAK1TYK2 | |
| SCHEMBL14842025 | 0.87 | SYK (1.00) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL17745676 | 0.87 | SYK (0.64) | SYKKCNH2JAK3MAPK3MAPK1 | |
| SCHEMBL14842284 | 0.86 | SYK (0.71) | SYKKCNH2JAK2MAP4K4MAPK3 | |
| SCHEMBL14852895 | 0.86 | SYK (0.71) | SYKKCNH2JAK2MAP4K4MAPK3 | |
| SCHEMBL16153729 | 0.86 | SYK (0.71) | SYKKCNH2JAK2MAP4K4MAPK3 | |
| SCHEMBL14852985 | 0.85 | SYK (1.00) | SYKKCNH2JAK2MAP4K4MAPK3 | |
| SCHEMBL14842576 | 0.85 | SYK (1.00) | SYKKCNH2JAK2MAP4K4MAPK3 | |
| SCHEMBL14842069 | 0.85 | SYK (0.72) | SYKKCNH2JAK2ZAP70 | |
| SCHEMBL14842105 | 0.85 | SYK (0.72) | SYKKCNH2MAPK3MAPK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763975-B1 | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | claimed |
| US-8987456-B2 | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | claimed |
| US-20140303206-A1 | 3-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | MERCK SHARP & DOHME LLC | 2014-10-09 | — | — | US | claimed |
| EP-2763975-B1 | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| US-8987456-B2 | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140303206-A1 | 3-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | MERCK SHARP & DOHME LLC | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303206-A1 | 3-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | SYK, BTK, LCK | SYK 1/4885KCNH2 2114/4885JAK2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.